Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) Revenue
Annual & quarterly revenue history · segment & region breakdown
ASND · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAscendis Pharma A/S trailing twelve-month (TTM) revenue is $0.87B, an increase of 90.22% year-over-year from $0.69B in FY2025.
Revenue trend
2025 – 2012 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.69B | +$0.33B | +90.22% |
| 2024-12-31 | $0.36B | +$0.10B | +36.34% |
| 2023-12-31 | $0.27B | +$0.22B | +421.20% |
| 2022-12-31 | $0.05B | +$0.04B | +557.93% |
| 2021-12-31 | $0.01B | +$0.00B | +11.87% |
| 2020-12-31 | $0.01B | -$0.01B | -48.01% |
| 2019-12-31 | $0.01B | +$0.00B | +26.41% |
| 2018-12-31 | $0.01B | +$0.01B | +591.57% |
| 2017-12-31 | $0.00B | -$0.00B | -66.78% |
| 2016-12-31 | $0.00B | -$0.00B | -43.26% |
Compare revenue vs peers
BiotechnologyCompare ASND revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Ascendis Pharma A/S receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Ascendis Pharma A/S reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in EUR.
Data sourced from Ascendis Pharma A/S's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ASND revenue · 4 questionsASND's trailing twelve-month (TTM) revenue is $0.87B. That is an increase of 90.22% year-over-year from $0.69B in FY2025.
▸ Source: FMP · Ascendis Pharma A/S SEC filings · GAAP · Ascendis Pharma A/S SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026